Seek Returns

ABBV vs. GILD: AbbVie vs. Gilead Sciences Stock Comparison

How do AbbVie (ABBV) and Gilead Sciences (GILD) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AbbVie (ABBV) and Gilead Sciences (GILD) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for AbbVie (ABBV) and Gilead Sciences (GILD)
Profile ItemABBVGILD
NameAbbVie Inc.Gilead Sciences Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization514.92 billion USD207.00 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateJanuary 2, 2013January 22, 1992
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ABBV
GILD
GSPC
Loading price history…
AbbVie (ABBV) vs. Gilead Sciences (GILD), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for AbbVie (ABBV) and Gilead Sciences (GILD). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for AbbVie (ABBV) and Gilead Sciences (GILD). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AbbVie (ABBV) and Gilead Sciences (GILD)
MetricABBVGILD
Total Return (1Y)37.33%45.69%
Total Return (3Y, Annualized)32.74%35.30%
Total Return (5Y, Annualized)24.73%25.00%

Risk Profile

Drawdown History

ABBV
GILD
GSPC
Loading price history…
AbbVie (ABBV) vs. Gilead Sciences (GILD), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for AbbVie (ABBV) and Gilead Sciences (GILD). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for AbbVie (ABBV) and Gilead Sciences (GILD)
MetricABBVGILD
Volatility (1Y, Annualized)25.65%27.57%
Beta (5Y)0.210.36
Max Drawdown (5Y)-21.92%-26.59%
Avg. Volume (3M)4.76M5.98M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ABBV and GILD are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AbbVie (ABBV) and Gilead Sciences (GILD)
MetricABBVGILD
Sharpe Ratio (1Y)1.291.50
Sortino Ratio (1Y)2.022.48

Profitability

ROE (TTM)

AbbVie (ABBV) has no ROE value reported for this period; Gilead Sciences (GILD) reports a negative figure of -22.45%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
ABBV
--

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-22.45%

Max
109.18%
Q3
6.23%
GILD
-22.45%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
AbbVie (ABBV) vs. Gilead Sciences (GILD): ABBV does not report ROE, so it has no value marker; GILD is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Gilead Sciences (GILD) reports a negative net margin of -12.46%, usually indicating a net loss over the period. Meanwhile AbbVie (ABBV) reports 15.67%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.67%

Max
18.05%
ABBV
15.67%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

-12.46%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
GILD
-12.46%
Min
-17.05%
Loading chart…
AbbVie (ABBV) vs. Gilead Sciences (GILD): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both AbbVie (ABBV) at 39.59% and Gilead Sciences (GILD) at 42.43% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.59%

Max
83.12%
ABBV
39.59%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

42.43%

Max
83.12%
GILD
42.43%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
AbbVie (ABBV) vs. Gilead Sciences (GILD): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for AbbVie (ABBV) and Gilead Sciences (GILD)
MetricABBVGILD
ROE (TTM)---22.45%
ROA (TTM)10.74%13.47%
Net Margin (TTM)15.67%-12.46%
Operating Margin (TTM)39.59%42.43%
Gross Margin (TTM)73.72%79.95%

Growth

Revenue Growth

Both AbbVie (ABBV) at 8.57% and Gilead Sciences (GILD) at 2.39% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
AbbVie (ABBV) vs. Gilead Sciences (GILD): A comparison of their Revenue Growth across different time periods.

EPS Growth

Gilead Sciences (GILD) at 1,684.21% clears its industry range for EPS growth, a much stronger earnings trajectory than AbbVie (ABBV) at -0.84%, which is closer to a typical peer reading.

Loading chart…
AbbVie (ABBV) vs. Gilead Sciences (GILD): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AbbVie (ABBV) and Gilead Sciences (GILD)
MetricABBVGILD
Revenue Growth (YoY)8.57%2.39%
Revenue Growth (3Y CAGR)1.75%2.57%
EPS Growth (YoY)-0.84%1,684.21%
EPS Growth (3Y CAGR)-29.03%23.04%

Financial Strength

Current Ratio (MRQ)

Both AbbVie (ABBV) at 0.87 and Gilead Sciences (GILD) at 1.38 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.87

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ABBV
0.87
Min
0.10

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
GILD
1.38
Min
0.10
Loading chart…
AbbVie (ABBV) vs. Gilead Sciences (GILD): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Gilead Sciences (GILD) carries debt-to-equity ratio of 2.02 against its industry range, while AbbVie (ABBV) reports no figure this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
ABBV
--

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.02

GILD
2.02
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
AbbVie (ABBV) vs. Gilead Sciences (GILD): ABBV does not report debt-to-equity ratio, so it has no value marker; GILD is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for AbbVie (ABBV) and Gilead Sciences (GILD)
MetricABBVGILD
Current Ratio (MRQ)0.871.38
Debt / Equity (MRQ)--2.02
Net Debt / EBITDA2.211.25

Dividends

Dividend Yield (TTM)

Both AbbVie (ABBV) at 2.40% and Gilead Sciences (GILD) at 1.94% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40%

ABBV
2.40%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.94%

GILD
1.94%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
AbbVie (ABBV) vs. Gilead Sciences (GILD): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Gilead Sciences (GILD) reports 43.46%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.35%

ABBV
117.35%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.46%

GILD
43.46%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
AbbVie (ABBV) vs. Gilead Sciences (GILD): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for AbbVie (ABBV) and Gilead Sciences (GILD)
MetricABBVGILD
Dividend Yield (TTM)2.40%1.94%
Dividend Payout Ratio (TTM)117.35%43.46%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: AbbVie (ABBV) trades at 50.05 times trailing earnings, ranked against its peers, while Gilead Sciences (GILD) has no P/E ratio this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

50.05

Max
85.34
ABBV
50.05
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
GILD
--
Loading chart…
AbbVie (ABBV) vs. Gilead Sciences (GILD): GILD does not report P/E ratio, so it has no value marker; ABBV is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both AbbVie (ABBV) at 7.80 and Gilead Sciences (GILD) at 6.68 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.80

Max
58.18
Q3
25.77
ABBV
7.80
Median
7.30
Q1
3.01
Min
0.01

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
GILD
6.68
Q1
3.01
Min
0.01
Loading chart…
AbbVie (ABBV) vs. Gilead Sciences (GILD): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Gilead Sciences (GILD) reports 15.88, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-112.34

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
ABBV
-112.34

GILD

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.88

GILD
15.88
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
AbbVie (ABBV) vs. Gilead Sciences (GILD): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for AbbVie (ABBV) and Gilead Sciences (GILD)
MetricABBVGILD
P/E Ratio (TTM)50.05--
P/S Ratio (TTM)7.806.68
P/B Ratio (MRQ)-112.3415.88
Free Cash Flow Yield (TTM)3.44%5.16%